Cogent Biosciences, Inc. COGT Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by Cogent Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.
The official record: Cogent Biosciences, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Cogent Biosciences, Inc.'s additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Cogent Biosciences, Inc.'s additional paid-in capital?
- Cogent Biosciences, Inc. (COGT) reported additional paid-in capital of $1.83B in Q1 2026.
- How has Cogent Biosciences, Inc.'s additional paid-in capital changed year-over-year?
- Cogent Biosciences, Inc.'s additional paid-in capital increased by 75.5% year-over-year, from $1.04B to $1.83B.
- What is the long-term trend for Cogent Biosciences, Inc.'s additional paid-in capital?
- Over 5 years (2020 to 2025), Cogent Biosciences, Inc.'s additional paid-in capital has grown at a 40.0% compound annual growth rate (CAGR), from $322.45M to $1.73B.
- What does additional paid-in capital mean?
- This represents the excess amount paid by investors for common shares over their par value. It is a key component of shareholders' equity that captures the capital raised through equity offerings beyond the nominal value of the stock. It reflects the historical market premium at which the company has issued its shares.